imigliptin (KBP-3853)
/ Sihuan Pharmaceutical
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 08, 2021
Dipeptidyl-Peptidase-IV Inhibitors, Imigliptin and Alogliptin, Improve Beta-Cell Function in Type 2 Diabetes.
(PubMed, Front Endocrinol (Lausanne))
- "After 13 days of treatment, imigliptin and alogliptin could decrease glycemic levels by improving beta-cell function. By comparing OMM with HOMA or SUIT results, glucose stimulation might be more sensitive for detecting changes in beta-cell function."
Journal • Diabetes • Metabolic Disorders • Transplantation • Type 2 Diabetes Mellitus
1 to 1
Of
1
Go to page
1